Financing ·
Kyverna Therapeutics, Inc. amended its $150.0 million non-dilutive term loan facility with Oxford Finance LLC to…
KYTXKyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. amended its $150.0 million non-dilutive term loan facility with Oxford Finance LLC to extend the availability of the remaining $15.0 million of Term A Loans through December 31, 2026, for an upfront fee of $187,500. The amendment also includes provisions for extending Term B and Term C loan tranches contingent upon full utilization of the remaining Term A funds. Kyverna Therapeutics, Inc. is a biotechnology company developing cell therapies for autoimmune diseases.